Expression of miR-146a in patients with ovarian cancer and its clinical significance

  • Authors:
    • Miłosz Wilczyński
    • Ewelina Żytko
    • Bożena Szymańska
    • Monika Dzieniecka
    • Marek Nowak
    • Justyna Danielska
    • Grzegorz Stachowiak
    • Jacek R. Wilczyński
  • View Affiliations

  • Published online on: June 23, 2017     https://doi.org/10.3892/ol.2017.6477
  • Pages: 3207-3214
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present retrospective study was to compare microRNA (miR)‑146a expression levels in primary tumors and omental metastases of 48 patients, who had undergone surgery for advanced ovarian serous cancer. Possible correlations between miR‑146a expression level and clinicopathological features were investigated, including chemosensitivity and survival. miR‑146a was evaluated in formalin‑fixed, paraffin‑embedded samples. miR‑146a expression level in primary tumors was demonstrated to be increased in comparison with normal ovary tissues (P=0.02) and metastases (P=0.01). A negative correlation was demonstrated between miR‑146a expression in primary tumors and serum levels of cancer antigen 125 (R=‑0.37; P=0.03) and Risk of Malignancy Algorithm index (R=‑0.79; P=0.0007). Overall survival positively correlated with miR‑146a expression in primary tumor tissue samples (R=0.38; P=0.01). Probability of survival was decreased in patients with low miR‑146a expression levels in primary tumor tissues (hazard ratio=0.21; P=0.003). Lower levels of miR‑146a in primary tumor tissue samples were correlated with a shorter progression‑free survival (P=0.04) and platinum‑resistance of metastases (P=0.006). In conclusion, miR‑146a may be a prognostic marker for serous ovarian cancer.
View Figures
View References

Related Articles

Journal Cover

September-2017
Volume 14 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wilczyński M, Żytko E, Szymańska B, Dzieniecka M, Nowak M, Danielska J, Stachowiak G and Wilczyński JR: Expression of miR-146a in patients with ovarian cancer and its clinical significance. Oncol Lett 14: 3207-3214, 2017
APA
Wilczyński, M., Żytko, E., Szymańska, B., Dzieniecka, M., Nowak, M., Danielska, J. ... Wilczyński, J.R. (2017). Expression of miR-146a in patients with ovarian cancer and its clinical significance. Oncology Letters, 14, 3207-3214. https://doi.org/10.3892/ol.2017.6477
MLA
Wilczyński, M., Żytko, E., Szymańska, B., Dzieniecka, M., Nowak, M., Danielska, J., Stachowiak, G., Wilczyński, J. R."Expression of miR-146a in patients with ovarian cancer and its clinical significance". Oncology Letters 14.3 (2017): 3207-3214.
Chicago
Wilczyński, M., Żytko, E., Szymańska, B., Dzieniecka, M., Nowak, M., Danielska, J., Stachowiak, G., Wilczyński, J. R."Expression of miR-146a in patients with ovarian cancer and its clinical significance". Oncology Letters 14, no. 3 (2017): 3207-3214. https://doi.org/10.3892/ol.2017.6477